Richard S. Levy - May 3, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
May 3, 2024
Transactions value $
$0
Form type
4
Date filed
5/7/2024, 04:46 PM
Previous filing
Apr 3, 2024
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +747 +9.61% 8.52K May 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +747 $0.00 747 May 3, 2024 Class A Common Shares 747 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -747 -100% $0.00* 0 May 3, 2024 Class A Common Shares 747 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs.